Acute Effects of Fibular Repositioning Taping on Balance, Jumping, and Sprint Performance

July 15, 2026 updated by: Selim Mahmut GÜNAY, Uludag University

The Acute Effect of Fibular Repositioning Taping on Balance, Jumping, and Sprint Performance in Healthy Individuals: A Randomized Controlled Trial

This randomized controlled trial aims to investigate the acute effects of fibular repositioning taping on balance, jumping, and sprint performance in healthy individuals. Eligible participants are randomly allocated to one of three groups: fibular repositioning taping, sham taping, or control. Physical performance and dynamic balance are assessed at baseline and after the intervention using functional outcome measures, including jumping tests, a 10-meter sprint test, and the Y Balance Test. The study is designed to determine whether fibular repositioning taping produces short-term changes in selected performance parameters compared with sham taping and no intervention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
90

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Selim M GÜNAY, Asst Prof
  • Phone Number: +90 539 462 8521
  • Email: mgselim1@gmail.com

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy individuals
  • Age between 18 and 30 years
  • Willingness to participate in the study and provide informed consent
  • Ability to perform balance, jump, and sprint performance tests

Exclusion Criteria:

  • History of lower extremity injury or surgery within the last 6 months
  • Presence of acute pain during testing
  • Neurological, orthopedic, or vestibular condition that may affect balance or performance
  • Previous experience of adverse reaction to taping material
  • Refusal to participate or inability to complete the study procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Fibular Repositioning Taping Group
Participants in this group receive fibular repositioning taping applied to the dominant ankle. Baseline assessments are performed before taping, and outcome measurements are repeated 30 minutes after the intervention.
Procedure: Fibular Repositioning Taping
Fibular repositioning taping is applied to the dominant ankle using a rigid taping technique intended to support fibular positioning. Outcome measurements are repeated 30 minutes after the application.
Sham Comparator: Sham Taping Group
Participants in this group receive a sham taping application with a similar appearance to the fibular repositioning taping but without therapeutic fibular repositioning. Baseline assessments are performed before taping, and outcome measurements are repeated 30 minutes after the application.
Procedure: Sham Taping
Sham taping is applied to the dominant ankle with a similar appearance to the active taping application but without therapeutic fibular repositioning or manual correction
No Intervention: Control Group
Participants in this group receive no taping intervention. Baseline assessments are performed, and outcome measurements are repeated after a 30-minute waiting period.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Y Balance Test
Time Frame: Baseline and 30 minutes after the intervention
Dynamic balance will be assessed using the Y Balance Test. The composite score will be calculated from reach distances and normalized to limb length. Higher composite scores indicate better dynamic balance performance.
Baseline and 30 minutes after the intervention
Horizontal Jump Test
Time Frame: Baseline and 30 minutes after the intervention
Horizontal jump performance will be assessed using the Horizontal Jump Test. The jump distance will be measured in centimeters from the starting line to the landing point. Greater distance indicates better horizontal jump performance.
Baseline and 30 minutes after the intervention
10-Meter Sprint Test
Time Frame: Baseline and 30 minutes after the intervention
Sprint performance will be assessed using the 10-meter sprint test. The time required to complete the 10-meter sprint will be recorded in seconds. Shorter times indicate better sprint performance.
Baseline and 30 minutes after the intervention
Vertical Jump Test
Time Frame: Baseline and 30 minutes after the intervention
Vertical jump performance will be assessed using the Vertical Jump Test. Jump height will be measured in centimeters. Greater jump height indicates better vertical jump performance.
Baseline and 30 minutes after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Uludag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 2, 2026

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 15, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 29, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 15, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 17, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 15, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2025/819/15-10

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be made publicly available in order to protect participant privacy and confidentiality.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings